查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
质子泵抑制剂的全球市场——2022-2029
市场调查报告书
商品编码
1146404

质子泵抑制剂的全球市场——2022-2029

Global Proton Pump Inhibitors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

质子泵抑制剂的市场规模预计到 2021 年将达到 30 亿美元，到 2029 年将达到 40 亿美元，在预测期内（2022-2029 年）以 4.9% 的复合年增长率增长。 .

质子泵抑制剂 (PPI) 是主要用于显着和持续降低胃酸过多、胃食管反流病和溃疡患者胃酸水平的药物。

市场动态

市场的增长在很大程度上是由消化性溃疡和其他胃肠道疾病的增加推动的，这是推动创新药物输送系统被接受的主要因素之一。此外，新产品的推出和消费者对新给药技术接受度的提高为市场参与者提供了巨大的发展潜力。

GERD 患病率上升和新的给药系统有望推动市场增长

推动市场增长的两个因素是胃食管反流病 (GERD) 患病率的上升和对创新药物输送技术的日益接受。质子泵抑製剂是 GERD 的标准治疗方法。

此外，诸如年龄、肥胖、胃排空延迟、与吸烟相关的习惯改变以及使用酒精、咖啡、高脂肪和油炸食品等风险因素是引起 GERD 的主要原因。根据联合国《世界人口老龄化报告》，2020年65岁及以上人口有7.27亿，预计到2050年将增至15亿。

此外，进入市场的主要公司正在开发新产品并推出新产品，以预测市场的未来潜力。例如，新泽西州 Insood Pharmaceuticals 的仿製药子公司 Xiromed LLC 于 2021 年 3 月推出了奥美拉唑缓释胶囊 20mg，这是 Prirose 的仿製药。这些药物的上市正在加速市场的扩张。

与质子泵抑制剂相关的副作用是市场增长的主要障碍

质子泵抑制剂存在结肠艰难梭菌感染的风险。长期使用 PPI 还可能增加与骨质疏鬆相关的髋部、腕部和脊柱骨折的风险。

COVID-19 影响分析

多项研究表明，服用质子泵抑制剂的人感染 COVID-19 的风险增加。该研究在 2020 年 8 月的一篇题为“质子泵抑制剂使用者增加感染 COVID-19 的风险”的文章中有所描述，涉及超过 53,000 名质子泵抑製剂使用者，其中 3,386 人患有 COVID-19。已报告 19 例阳性反应。建议接受质子泵抑制剂治疗的患者减少药物摄入量，除非在紧急情况下避免使用这些药物。预计这将影响市场增长。因此，COVID-19将对增加截肢的调查市场的扩大产生相当大的影响。

行业分析

全球质子泵抑製剂市场根据波特五力分析、监管分析、报销分析、供应链分析、定价分析和管道分析等各种行业因素对市场进行了深入分析。

细分分析

埃索美拉唑细分市场有望在全球质子泵抑製剂市场占据最大市场份额

埃索美拉唑预计将占大部分收入，因为它主要用于治疗 GERD、胃灼热和其他胃酸过多的症状和问题。此外，即将到来的从非处方药到处方药的转变可能会对销售产生重大影响。

此外，市场上的主要竞争对手正专注于研发和市场拓展工作，以向市场推出新的可靠配方。例如，2020 年 7 月，Cadila Pharmaceuticals 在印度推出了商品名为 Esiloc 的埃索美拉唑片，用于治疗胃酸过多和药物性胃炎。

市场进入者的战略行动也在加速这一细分市场的扩张。例如，2021年3月，第一三共株式会社从日本阿斯利康手中收购了质子泵抑製剂耐信10mg和20mg胶囊以及耐信10mg和20mg悬浮颗粒（埃索美拉唑镁）的销售和分销权。

区域分析

北美在质子泵抑制剂的全球市场中占有最大的市场份额

北美目前在质子泵抑制剂市场占据主导地位，预计在预测期内将继续占据主导地位，且不会出现明显变化。然而，由于不健康生活方式的增加，GERD 在美国、加拿大和墨西哥变得越来越普遍。根据美国国家糖尿病、消化和肾臟疾病研究所 2020 年的统计数据，大约 20% 的美国人患有 GERD。

质子泵抑製剂是美国最常用的处方药之一，在过去几年中，美国门诊 PPI 的使用量激增。许多公司还在品牌推广方面进行了大量投资。美国医师学会注意到 PPI 的使用越来越多，并发起了一项鼓励正确使用 PPI 的运动。

此外，仿製药的上市有望对市场产生影响。例如，雷迪博士实验室有限公司于 2021 年 2 月推出了口腔崩解片兰索拉唑 DR。本品为 Prevacidsolutab 缓释口腔崩解片 15mg、30mg 的治疗等效仿製药，已获得美国食品和药物管理局 (USFDA) 批准。此类仿製药的推出正在加速市场的扩张。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按药物类型划分的市场细分
  • DataM CLO 场景

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 胃食管反流病 (GERD) 患病率增加
      • 新药物输送系统的采用范围扩大
  • 抑制因素
    • 增加仿製药的使用
  • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 监管分析
  • 供应链分析
  • 流行病学分析
  • 管道分析
  • 保险报销分析
  • 未满足的需求

第 6 章按药物类型分类

  • 非处方药
    • Omeprazole
    • Lansoprazole
    • Esomeprazole
    • 其他非处方药
  • 处方药
    • Rabeprazole
    • Dexlansoprazole
    • Pantoprazole
    • 其他药物

第 7 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 8 章竞争格局

  • 竞争场景
  • 竞争性质子泵抑製剂策略分析
  • 比较产品组合分析
  • 市场情况/份额分析
  • 併购分析

第 9 章公司简介

  • Bayer AG
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • AstraZeneca
  • Pfizer, Inc
  • Eli-Lilly
  • Teva Pharmaceuticals
  • Cadila pharmaceuticals
  • Janssen Global Services
  • Takeda Pharmaceuticals
  • Eisai Pharmaceuticals

第 10 章质子泵抑制剂的全球市场-DataM

简介目录
Product Code: DMPH1407

Market Overview

Proton Pump Inhibitors Market size was valued US$ 3.0 billion in 2021 and is estimated to reach US$ 4.0 billion by 2029, growing at a CAGR of 4.9% during the forecast period (2022-2029).

Proton pump initiators (PPIs) are medications that are primarily used to significantly and persistently reduce the levels of stomach acid in people with hyperacidity, gastroesophageal reflux disease, and ulcers.

Market Dynamics

The growth of the market is majorly driven by increasing number of peptic ulcers and other gastrointestinal problems, one of the primary factors driving the acceptance of innovative drug delivery systems. In addition, new product introductions and rising consumer acceptance of novel medicine delivery technologies present market players with enormous development potential.

Increasing prevalence of GERD coupled with novel drug delivery systems are expected to drive market growth

The two main drivers driving the growth of the market are the rising prevalence of gastroesophageal reflux disease (GERD) and the expanding acceptability of innovative medication delivery technologies. Proton pump inhibitors are the gold standard treatments for GERD.

Additionally, the main causes of GERD include risk factors like age, obesity, delayed stomach emptying, changing smoking-related habits, and use of alcohol, coffee, fatty, and fried meals. Furthermore, according to a report by the United Nations titled "World Population Ageing Report, 2020," there were 727 million individuals in the world who were 65 or older as of 2020, and that figure is expected to increase to 1.5 billion by 2050.

Additionally, major industry participants are developing novel products and launching new products to take advantage of market prospects. For instance, the generic version of Prilose, Omeprazole Delayed-Release Capsules, 20mg, was introduced in March 2021 by Xiromed LLC, the generic subsidiary of Insud Pharmaceuticals in New Jersey. Such medicine launches are accelerating the market's expansion.

The side effects associated with the proton pump inhibitors are the major factors hindering the growth of the market

Proton pump inhibitors lead to a risk of Clostridium difficile infection of the colon. Also, the long-term usage of PPI may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.

COVID-19 Impact Analysis

Numerous studies have shown that people taking proton pump inhibitors have a higher risk of COVID-19. More than 53,000 users of proton pump inhibitors took part in the study described in the August 2020 article titled "Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors," 3,386 of whom reported having tested positive for COVID-19. Patients undergoing proton-pump inhibitor therapy are encouraged to consume fewer drugs and avoid these medications unless there is an emergency. This factor is expected to impact market growth. Therefore, COVID-19 considerably affects the expansion of the market under investigation.an increase in amputations.

Industry Analysis

The global proton pump inhibitors market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, pipeline analysis etc.

Segment Analysis

Esomeprazole segment is expected to hold the largest market share in global proton pump inhibitors market

Since it is mainly used to treat the signs and symptoms of GERD, heartburn, and other problems involving excessive stomach acids, esomeprazole is anticipated to account for a sizeable portion of the income. Additionally, the drug's imminent transition from an over-the-counter (OTC) drug to a prescription-only medication will likely impact sales considerably.

Major market competitors are also concentrating on R&D and market expansion initiatives to introduce new and dependable formulations to the market. For instance, in July 2020, Cadila Pharmaceuticals introduced esomeprazole tablets under the trade name Esiloc in India to treat hyperacidity and medication-induced gastritis.

The market participants' strategic actions are also accelerating the segment's expansion. For example, in March 2021 Daiichi Sankyo Co., Ltd. gave AstraZeneca in Japan the marketing and distribution rights for the proton pump inhibitor Nexium 10 mg and 20 mg capsules and Nexium 10 mg and 20 mg granules for suspension (esomeprazole magnesium).

Geographical Analysis

North America region holds the largest market share in the global proton pump inhibitors market

North America presently dominates the proton pump inhibitors market, and it is predicted that it will continue to do so during the forecast period without experiencing any notable changes. However, due to a rise in unhealthy lifestyles, GERD is becoming more prevalent in the United States, Canada, and Mexico. About 20% of Americans, according to the National Institute of Diabetes and Digestive and Kidney Diseases Statistics of 2020, have GERD.

Proton pump inhibitors are one of the most commonly prescribed medications in the US, and during the past few years, ambulatory settings throughout the country have seen an upsurge in PPI use. Additionally, many companies are investing extensively in brand promotion. The American Board of Internal Medicine took notice of the growing usage of PPIs and launched a campaign to encourage their proper use.

Additionally, it is anticipated that generic product launches will affect the market. As an illustration, Dr Reddy's Laboratories Ltd. introduced lansoprazole DR, orally disintegrating tablets, in February 2021. This product is a therapeutically equivalent generic version of Prevacid soluTab delayed-release orally disintegrating tablets, 15 mg and 30 mg, and it has received approval from the US Food and Drug Administration (USFDA). Such generic medicine introductions are accelerating the market's expansion.

Competitive Landscape

The proton pump inhibitors market is highly competitive, owing to the presence of big brands. Also, the market is highly fragmented due to the presence of several large and regional players. The key players which are contributing to the growth of the global market include Bayer, AstraZeneca, Pfizer, Inc, Eli-Lilly, Teva Pharmaceuticals, Cadila pharmaceuticals, Janssen Global Services, Takeda Pharmaceuticals and Eisai Pharmaceuticals.

Key Companies to Watch

Pfizer Inc:

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. The company also offers orthodontic solutions, Proton Pump Inhibitors solutions, surgical devices, consumer health, micro fluidics, medical grade tapes and adhesive technologies to medical device manufacturers.

Product Portfolio: PROTONIX- PROTONIX is a proton pump inhibitor indicated for short-Term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD).

The global proton pump inhibitors market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug types
  • 3.2. DataM CLO Scenario

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of gastroesophageal reflux disease (GERD)
      • 4.1.1.2. Increasing acceptance of novel drug delivery systems
  • 4.2. Restraints
    • 4.2.1. Increasing use of generic drugs
  • 4.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porters Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Epidemiology Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. By Drug Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Over the Counter Drugs
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.2.3. Omeprazole
    • 6.2.4. Lansoprazole
    • 6.2.5. Esomeprazole
    • 6.2.6. Other OTC Drugs
  • 6.3. Prescription Drugs
    • 6.3.1. Rabeprazole
    • 6.3.2. Dexlansoprazole
    • 6.3.3. Pantoprazole
    • 6.3.4. Other Prescription Drugs

7. By Region

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 7.3. Market Attractiveness Index, By Region
  • 7.4. North America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.4.4.1. US
      • 7.4.4.2. Canada
      • 7.4.4.3. Mexico
  • 7.5. Europe
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.5.4.1. Germany
      • 7.5.4.2. UK
      • 7.5.4.3. France
      • 7.5.4.4. Italy
      • 7.5.4.5. Spain
      • 7.5.4.6. Rest of Europe
  • 7.6. South America
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.6.4.1. Brazil
      • 7.6.4.2. Argentina
      • 7.6.4.3. Rest of South America
  • 7.7. Asia Pacific
    • 7.7.1. Introduction
    • 7.7.2. Key Region-Specific Dynamics
    • 7.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
    • 7.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 7.7.4.1. China
      • 7.7.4.2. India
      • 7.7.4.3. Japan
      • 7.7.4.4. Australia
      • 7.7.4.5. Rest of Asia Pacific
  • 7.8. Middle East and Africa
    • 7.8.1. Introduction
    • 7.8.2. Key Region-Specific Dynamics
    • 7.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type

8. Competitive Landscape

  • 8.1. Competitive Scenario
  • 8.2. Competitor Proton Pump Inhibitor Strategy Analysis
  • 8.3. Comparative Product Portfolio Analysis
  • 8.4. Market Positioning/Share Analysis
  • 8.5. Mergers and Acquisitions Analysis

9. Company Profiles

  • 9.1. Bayer AG
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio and Description
    • 9.1.3. Key Highlights
    • 9.1.4. Financial Overview
  • 9.2. AstraZeneca
  • 9.3. Pfizer, Inc
  • 9.4. Eli-Lilly
  • 9.5. Teva Pharmaceuticals
  • 9.6. Cadila pharmaceuticals
  • 9.7. Janssen Global Services
  • 9.8. Takeda Pharmaceuticals
  • 9.9. Eisai Pharmaceuticals

(LIST NOT EXHAUSTIVE)

10. Global Proton Pump Inhibitors Market - DataM

  • 10.1. Appendix
  • 10.2. About Us and Services
  • 10.3. Contact Us